曲美他嗪治疗冠心病心力衰竭的临床疗效及安全性研究

Trimetazidine treatment of coronary heart disease(CHD) heart failure clinical curative effect and security research

目的:研究冠心病心力衰竭用曲美他嗪的疗效及安全性。方法:选择2015年4月~2017年3月本科接诊的冠心病心力衰竭患者76例,利用抽签法,将76例患者随机等分成甲组和乙组。两组都予以常规治疗,甲组同时加用曲美他嗪。分析比较两组临床治疗的效果与安全性。结果:甲组的不良反应发生率为5.26%,和乙组的13.16%比较并无显著差异,P>0.05。甲组治疗的总有效率为97.37%,明显比乙组的78.95%高,P<0.05。结论:利用曲美他嗪对冠心病心力衰竭进行治疗,可显著改善其射血功能,促进病情康复,确保用药安全。

Objective： to study the coronary heart disease with heart failure the curative effect and safety of trimetazidine. Methods： choose between April 2015 and March 2017 undergraduate departments of 76 cases of coronary heart disease （CHD） heart failure patients, using the lottery method, 76 cases of patients were randomly divided into first division and group h. Have regular treatment, the two groups of students at the same time combined with trimetazidine. Analysis to compare the effect and security of the two groups of clinical treatment. Results： the first division of the incidence of adverse reactions was 5.26%, and 13.16% of the group b was no significant difference, P〉0.05. Students＇ treatment the total effective rate was 97.37%, significantly higher than 78.95% of the group b, P〈0.05. Conclusion： the use of trimetazidine treatment of coronary heart disease （CHD） heart failure patients, can significantly improve the ejection function, promoting disease rehabilitation, ensure drug safety.